Page 105«..1020..104105106107..110120..»

Category Archives: Cell Medicine

Stem cell boss joins board he funded

Posted: July 9, 2014 at 9:53 pm

Alan Trounson, then president of the California Institute for Regenerative Medicine, poses for a portrait at his offices in San Francisco, Monday, March 9, 2009. (AP Photo/Eric Risberg)

The former head of California's stem cell agency, which is handing out $3 billion of voter-approved funds for research, has joined the board of a major grant recipient one week after leaving his post.

Alan Trounson, the former president of the California Institute for Regenerative Medicine, has joined the board of StemCells Inc., the recipient of $19.4 million from the agency.

The agency has been grappling with potential conflicts of interest, some of which are built into its governance under Proposition 71, approved by voters in 2004. CIRM paid $700,000 for a report last year making recommendations on how to mitigate conflicts.

Trounson's move has reignited debate over the issue.

"The announcement raises serious and obvious concerns on a number of fronts," Chairman Jonathan Thomas wrote to his colleagues on the CIRM board. "Under state law, however, it is permissible for Dr. Trounson to accept employment with a CIRM-funded company. Nonetheless, state law does impose some restrictions on Dr. Trounsons post-CIRM employment activities.

Board members will be forbidden to discuss the company with Trounson for one year after his departure, Thomas wrote.

Randy Mills, Trounson's successor as agency president, said in a statement Wednesday that "in the interests of transparency and good governance we will be conducting a full review of all CIRM activities relating to StemCells Inc.

"We take even the appearance of conflicts of interest very seriously," Mills said in the statement.

Not only board members, but CIRM employees are being reminded of the conflict of interest rules.

See original here:
Stem cell boss joins board he funded

Posted in Cell Medicine | Comments Off on Stem cell boss joins board he funded

Keck Medicine pushing into O.C. with oncology network acquisition

Posted: July 9, 2014 at 9:53 pm

Keck Medicine of USC has acquired a small oncology network, Orange Coast Oncology Hematology, to expand its growing presence in Orange County.

Keck intends to change the name of the newly acquired network to USC Oncology/Hematology, which will operate out of offices in Newport Beach and Irvine.

Orange County cancer patients will now have access to university-based treatment, including clinical trials and genetic stem cell research, without having to drive to Los Angeles, said Thomas Jackiewicz, chief of Keck Medicine of USC.

The acquisition is part of Keck Medicines ongoing expansion into Orange County, Jackiewicz said. Keck Medicine has previously affiliated with Hoag Memorial Hospital Presbyterian in Newport Beach as part of its Orange County outreach.

We realized a lot of people were leaving Orange County for their cancer care, Jackiewicz said. We really wanted to make it about the patient and try to bring cancer care closer to home.

Under the acquisition, which was announced Wednesday, physicians with the former Orange Coast Oncology Hematology will become faculty at Keck School of Medicine. The physicians joining Keck include Greg Richard Angstreich, Minh D. Nguyen, George B. Semeniuk III, Dilruba Haque and Louis VanderMolen.

Originally posted here:
Keck Medicine pushing into O.C. with oncology network acquisition

Posted in Cell Medicine | Comments Off on Keck Medicine pushing into O.C. with oncology network acquisition

Johns Hopkins Researchers Locate Genetic Variant Associated With Schizophrenia

Posted: July 6, 2014 at 2:44 am

July 5, 2014

redOrbit Staff & Wire Reports Your Universe Online

According to a new study appearing in the July 3 edition of the journal Cell Stem Cell, researchers from the Johns Hopkins University School of Medicine have uncovered a new genetic variant that could result in certain people having a predisposition to schizophrenia.

While there are many genetic variants that could increase the risk of developing a psychiatric disorder, they are insufficient to cause these diseases, the researchers explained. Now, however, the Johns Hopkins researchers have described a new strategy that could reveal how these so-called subthreshold genetic risks could impact the development of a persons nervous system by interacting with other risk factors.

This is an important step toward understanding what physically happens in the developing brain that puts people at risk of schizophrenia, senior author Dr. Guo-li Ming explained in a statement Thursday. Dr. Ming is a professor of neurology and neuroscience in the Johns Hopkins University School of Medicines Institute for Cell Engineering who worked on the study along with her husband, Dr. Hongjun Song.

In their study, Dr. Ming, Dr. Song and their colleagues explained that they used a multifaceted approach to find out why copy number variants in an area of the genome labeled 15q11.2 are prominent risk factors not just for schizophrenia, but for autism as well. Deletion of this part of a genome is associated with an increased risk of schizophrenia, but possessing extra copies results in an elevated risk of autism.

Their research focused on using a method which allows a patients skin cell to be reprogrammed into induced pluripotent stem cells (iPSCs), which can in turn be coaxed into creating any other type of cell. Using this technology, the study authors obtained stem cells from people with schizophrenia who were missing part of 15q11.2 on one of their chromosomes, ultimately coaxing them into neural progenitor cells, which are found in the developing brain.

By observing the process, the researchers found deficiencies during nerve development that could be linked to the gene CYFIP1, which maintains the structure of a nerve cell. By blocking the expression of this gene in developing mouse embryos, they found defects in the formation of the brains cerebral cortex, which plays a key role in consciousness.

The next step was to determine how this gene could interact with other factors, and they discovered that mutations in a pair of genes within a particular cellular pathway linked to CYFIP1 resulted in a significant increase in schizophrenia risk. According to the study authors, their research supports the belief that multiple factors in a single pathway could interact with one another to impact a patients potential risk for psychiatric disorders.

The reason, the team found, is that CYFIP1 plays a role in building the skeleton that gives shape to each cell, and its loss affects spots called adherens junctions where the skeletons of two neighboring cells connect, the university explained. A lack of CYFIP1 protein also caused some of the mice neurons to wind up in the brains wrong layer.

View post:
Johns Hopkins Researchers Locate Genetic Variant Associated With Schizophrenia

Posted in Cell Medicine | Comments Off on Johns Hopkins Researchers Locate Genetic Variant Associated With Schizophrenia

Nuclear Transfer Proven An Effective Method In Stem Cell Production

Posted: July 3, 2014 at 9:42 pm

July 3, 2014

redOrbit Staff & Wire Reports Your Universe Online

A new process known as somatic cell nuclear transfer is far better and much more accurate when it comes to coaxing embryonic stem cells out of human skin tissue, according to new research appearing in Tuesdays edition of the journal Nature.

Scientists from Oregon Health & Science University (OHSU), the University of California-San Diego (UCSD) School of Medicine and the Salk Institute for Biological Studies created stem cells using two different methods: nuclear transfer, which involves moving genetic material from a skin cell into an empty egg cell, and a more traditional method in which activating a small number of genes reverts adults cells back to an embryonic state.

Experts believe that stem cell therapies could someday be used to replace human cells damaged through injury or illness, including spinal cord injuries, diabetes, Parkinsons disease and multiple sclerosis. Human embryonic stem cells (ES cells), which are cells cultured from discarded embryos, are viewed by scientists as the gold standard of the field, and the new study reports that somatic cell nuclear transfer (SCNT) more closely resembled ES cells.

This marks the first time that researchers had directly compared the SCNT method with the induced pluripotent stem cell (iPS cell) technique, and in a statement, co-senior author and UCSD assistant professor in reproductive medicine Dr. Louise Laurent explained that the nuclear transfer ES cells were more completely reprogrammed and had fewer alterations in gene expression and DNA methylation levels than the iPS cells.

Access to actual human embryonic stem cells (hESCs) has been limited in the US due to ethical and logistical issues, forcing researchers to devise other methods to create stem cells, the study authors explained. Typically, that means creating iPS cells by taking adult cells and adding in a mixture of genes that regress those cells to a pluripotent stem-cell state. Those cells can then be coaxed into cells resembling those found in the heart or brain.

Over the past year, however, an OHSU-led team of researchers have built upon somatic cell nuclear transfer (the same technique used for cloning organisms) to transplant the DNA-containing nucleus of a skin cell into an empty human egg. Once completed, the combination naturally matures into a group of stem cells.

For the first time, the OHSU, UCSD and Salk Institute researchers conducted a direct, in-depth comparison of the two different methods. They created four nuclear transfer ES cell lines and seven iPS cell lines using the same skin cells as the donor genetic material source, and then compared them to a pair of standard human ES lines.

A battery of standard tests revealed that all 13 cell lines were shown to be pluripotent. However, when the researchers used powerful genomic techniques to take a closer look at the DNA methylation (a biochemical process responsible for turning genes on or off) and the gene expression signatures of each cell line, they discovered that the nuclear transfer ES cells more closely resembled those of ES cells than did iPS cells in both characteristics.

More here:
Nuclear Transfer Proven An Effective Method In Stem Cell Production

Posted in Cell Medicine | Comments Off on Nuclear Transfer Proven An Effective Method In Stem Cell Production

Global Stem Cells Group Subsidiary Regenestem Announces Grand Opening of State-of-the-Art Regenestem Asia Stem Cell …

Posted: July 3, 2014 at 9:49 am

Miami (PRWEB) July 01, 2014

Global Stem Cells Group announced the grand opening of Regenestem Asia in Manila, Philippines, adding a new state-of-the-art clinic to the international stem cell medicine company's growing worldwide presence. With clinics in Miami, New York, Los Angeles and Dubai, Regenestem Asia now offers the same comprehensive stem cell treatments and experienced medical staff that have fueled the company's worldwide growth.

The launch of Regenestem Asia is a collaborative effort between Global Stem Cells Group and Eric Yalung, M.D. of the Cosmetic Surgery Institute-Manila, Inc., a prominent plastic surgeon committed to taking stem cell medicine, research and practice in the Philippines to a world-class level. The first Regenestem brand clinic in the Philippines, Regenestem Asia is a 22,000 square foot facility with a focus on offering the most advanced protocols in cosmetic cellular medicine to patients from around the world.

Under Yalung's leadership as Regenestem Medical Director, patients will receive the latest and least-invasive techniques in Stem Cell medicine available. Yalung is joined by a team of talented stem cell specialists to provide world-class patient treatment and follow-up care under the Regenestem brand.

In addition to cosmetic treatments, Regenestem offers stem cell treatments for arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes and multiple sclerosis among many other medical conditions at various facilities worldwide.

As part of its commitment to maintaining the highest standards in service and technology, Regenestem Asia provides an international staff experienced in administering the leading cellular therapies available.

Like all Regenestem facilities, Regenestem Asia is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

For more information, visit the Regenestem website, email bnovas(at)regenestem(dot)com or call 305-224-1858.

About Regenestem:

Regenestem is a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialists-professionals trained in the latest cutting-edge techniques in cellular medicine-Regenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.

More:
Global Stem Cells Group Subsidiary Regenestem Announces Grand Opening of State-of-the-Art Regenestem Asia Stem Cell ...

Posted in Cell Medicine | Comments Off on Global Stem Cells Group Subsidiary Regenestem Announces Grand Opening of State-of-the-Art Regenestem Asia Stem Cell …

2014 World Stem Cell Summit presented by GPI, Mary Ann Liebert, Inc, and GEN

Posted: June 27, 2014 at 7:46 am

PUBLIC RELEASE DATE:

25-Jun-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 25, 2014Mary Ann Liebert, Inc., publishers website and Genetic Engineering & Biotechnology News (GEN) are proud to announce that they will again serve as joint platinum media sponsors of the Genetics Policy Institute 2014 World Stem Cell Summit that will take place at the Marriott River Center, December 4-6, 2014 in San Antonio, Texas.

In a new collaborative effort in 2014, Mary Ann Liebert, Inc. will also organize a World Stem Cell Summit panel, comprised of leading editors from their peer-reviewed journals intersecting the field to predict the most innovative translational research that will impact regenerative medicine in the next five years.

Mary Ann Liebert, Inc. will also publish the 2014 World Stem Cell Report as a special supplement to the peer-reviewed journal Stem Cells and Development. Dr. Graham Parker, Editor-in-Chief of Stem Cells and Development, and Bernard Siegel, Executive Director of Genetics Policy Institute (GPI), will serve as Co-Editors-in-Chief of the Report, joined by Rosario Isasi (McGill University) as Managing Editor. The World Stem Cell Report will be made available to all subscribers of Stem Cells and Development and attendees of the World Stem Cell Summit. It will also be available free online in 106 developing countries, courtesy of the Publisher, to facilitate global stem cell research.

"We are very pleased to expand our collaboration with Mary Ann Liebert, Inc., and GEN," says Bernard Siegel, Founder and Co-chair of the Summit. "The commitment by those prestigious publishers to journalistic integrity and scientific knowledge and education matches our enthusiasm to advance the field of stem cells and regenerative medicine for the betterment of humanity. We look forward to working with Graham Parker and the skilled editorial team at Stem Cells and Development to publish our annual Report. We are especially excited to have the expertise of the Liebert editors engaged on the program at the World Stem Cell Summit."

"The World Stem Cell Summit is unequivocally a paramount meeting that brings together the leaders in the field from academia, industry, and business, thereby ensuring the advancement of collaborative opportunities," says Mary Ann Liebert, publisher & CEO of both Stem Cells and Development and GEN. "Bernie Siegel and GPI also recognize the importance of public advocacy at this most important international conference. Mary Ann Liebert, Inc. is delighted to expand our own collaboration with Bernie Siegel and GPI and to publish the 2014 Report.

GEN Editor-in-Chief John Sterling stated, "The World Stem Cell Summit is the critical global meeting, providing the best opportunity for the GEN community to participate in the world of regenerative medicine. Our platinum media sponsorship allows GEN readers and advertisers to have a front row seat to listen and learn from the top experts on the very dynamic and expertly conceptualized Summit platform."

The Summit program delivers on the "big picture," featuring over 200 prominent scientists, business leaders, regulators, policy-makers, advocates, economic development officers, experts in law and ethics, and visionary gurus who will discuss the latest scientific discoveries, business models, legal and regulatory solutions, and best practices. The Summit is expected to attract attendees from more than 40 nations.

Read this article:
2014 World Stem Cell Summit presented by GPI, Mary Ann Liebert, Inc, and GEN

Posted in Cell Medicine | Comments Off on 2014 World Stem Cell Summit presented by GPI, Mary Ann Liebert, Inc, and GEN

Pushing cells towards a higher pluripotency state

Posted: June 24, 2014 at 11:48 pm

Stem cells have the unique ability to become any type of cell in the body. Given this, the possibility that they can be cultured and engineered in the laboratory makes them an attractive option for regenerative medicine. However, some conditions that are commonly used for culturing human stem cells have the potential to introduce contaminants, thus rendering the cells unusable for clinical use. These conditions cannot be avoided, however, as they help maintain the pluripotency of the stem cells.

In a study published in Scientific Reports, a group from the RIKEN Center for Life Science Technologies in Japan has gained new insight into the role of CCL2, a chemokine known to be involved in the immune response, in the enhancement of stem cell pluripotency. In the study, the researchers replaced basic fibroblast growth factor (bFGF), a critical component of human stem cell culture, with CCL2 and studied its effect. The work showed that CCL2 used as a replacement for bFGF activated the JAK/STAT pathway, which is known to be involved in the immune response and maintenance of mouse pluripotent stem cells. In addition, the cells cultured with CCL2 demonstrated a higher tendency of colony attachment, high efficiency of cellular differentiation, and hints of X chromosome reactivation in female cells, all markers of pluripotency.

To understand the global effects of CCL2, the researchers compared the transcriptome of stem cells cultured with CCL2 and those with bFGF. They found that stem cells cultured with CCL2 had higher expression of genes related to the hypoxic response, such as HIF2A (EPAS1). The study opens up avenues for further exploring the relationship between cellular stress, such as hypoxia, and the enhancement of pluripotency in cells. Yuki Hasegawa of CLST, who led the study, says, "Among the differentially expressed genes, we found out that the most significantly differentially expressed ones were those related to hypoxic responses, and hypoxia is known to be important in the progression of tumors and the maintenance of pluripotency. These results could potentially contribute to greater consistency of human induced pluripotent stem cells (iPSCs), which are important both for regenerative medicine and for research into diseases processes."

As a way to apply CCL2 towards the culturing of human iPSCs with more consistent quality, the researchers developed dishes coated with CCL2 and LIF protein beads. This allowed stem cells to be cultured in a feeder-free condition, preventing the risk that viruses or other contaminants could be transmitted to the stem cells. While the exact mechanisms of how CCL2 enhances pluripotency has yet to be elucidated, this work highlights the usefulness of CCL2 in stem cell culture.

Story Source:

The above story is based on materials provided by RIKEN. Note: Materials may be edited for content and length.

Go here to read the rest:
Pushing cells towards a higher pluripotency state

Posted in Cell Medicine | Comments Off on Pushing cells towards a higher pluripotency state

Time-lapse study reveals bottlenecks in stem cell expansion

Posted: June 24, 2014 at 11:48 pm

PUBLIC RELEASE DATE:

12-Jun-2014

Contact: Hannah Postles h.postles@sheffield.ac.uk 01-142-221-046 University of Sheffield

A time-lapse study of human embryonic stems cells has identified bottlenecks restricting the formation of colonies, a discovery that could lead to improvement in their use in regenerative medicine.

Biologists at the University of Sheffield's Centre for Stem Cell Biology led by Professor Peter Andrews and engineers in the Complex Systems and Signal Processing Group led by Professor Daniel Coca studied human pluripotent stem cells, which are a potential source of cells for regenerative medicine because they have the ability to produce any cell type in the body.

However, using these stem cells in therapies is currently hampered by the fact they can acquire genetic changes during prolonged culture which are non-random and resemble mutations in cancer cells.

Researchers used time-lapse imaging of single human embryonic stem cells to identify aspects of their behaviour that restrict growth and would be targets for mutations that allow cells to grow more efficiently.

Dr Ivana Barbaric, from the University of Sheffield's Department of Biomedical Science, said: "We study pluripotent stem cells, which have huge potential for use in regenerative medicine due to their ability to become any cell in the human body. A pre-requisite for this is maintaining large numbers of undifferentiated cells in culture. However, there are several obstacles such as cells tend to die extensively during culturing and they can mutate spontaneously. Some of these genetic mutations are known to provide stem cells with superior growth, allowing them to overtake the culture a phenomenon termed culture adaptation, which mimics the behaviour of cancer cells.

"In order for pluripotent stem cells to be used safely in regenerative medicine we need to understand how suboptimal culture conditions, for example culturing cells at low split ratios, affect the cells and can lead to culture adaptation."

The team's research combined the use of time-lapse microscopy, single-cell tracking and mathematical modelling to characterise bottlenecks affecting the survival of normal human embryonic stem cells and compared them with adapted cells.

Originally posted here:
Time-lapse study reveals bottlenecks in stem cell expansion

Posted in Cell Medicine | Comments Off on Time-lapse study reveals bottlenecks in stem cell expansion

Stem cell-based transplantation approach improves recovery from stroke

Posted: June 24, 2014 at 11:48 pm

PUBLIC RELEASE DATE:

19-Jun-2014

Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press

Stroke is a leading cause of death and disability in developed countries, and there is an urgent need for more clinically effective treatments. A study published by Cell Press June 19th in Stem Cell Reports reveals that simultaneous transplantation of neural and vascular progenitor cells can reduce stroke-related brain damage and improve behavioral recovery in rodents. The stem cell-based approach could represent a promising strategy for the treatment of stroke in humans.

"Our findings suggest that early cotransplantation treatment can not only replace lost cells, but also prevent further deterioration of the injured brain following ischemic stroke," says senior study author Wei-Qiang Gao of Shanghai Jiaotong University. "With the development of human embryonic and induced pluripotent stem cell technology, we are optimistic about the potential translation of our research into clinical use."

The most common kind of stroke, known as ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. Although a medicine called tissue plasminogen activator can break up blood clots in the brain, it must be given soon after the start of symptoms to work, and there are no other clinically effective treatments currently available for this condition. Stem cell transplantation represents a promising therapeutic strategy, but transplantation of either neural progenitor cells or vascular cells has shown restricted therapeutic effectiveness.

In the new study, Gao teamed up with colleagues at Shanghai Jiao Tong University, including Jia Li, Yaohui Tang, and Guo-Yuan Yang, to test whether cotransplantation of both neural and vascular precursor cells would lead to better outcomes. They induced ischemic stroke in rats and then simultaneously injected neural and vascular progenitor cells from mice into the stroke-damaged rat brains 24 hours later. The transplanted precursor cells turned into all major types of vascular and brain cells, including mature, functional neurons. The resulting vascular cells developed into microvessels, while the grafted neural cells produced molecules known to stimulate the growth of both neurons and vessels.

"This is the first study to use embryonic stem cell-derived vascular progenitor cells together with neural progenitor cells to treat ischemic stroke," Gao says. "These two types of progenitors generate nearly all types of brain cells, including endothelial cells, pericytes/smooth muscle cells, neurons, and astrocytes, resulting in better restoration of neurovascular units and better replacement of the lost cells in the stroke model. A previously reported cotransplantation approach published in the journal Stem Cells in 2009 (doi: 10.1002/stem.161) was limited because it did not use vascular precursor cells capable of turning into all major types of vascular cells important for recovery. Our findings here suggest that cotransplantation of the two types of cells that restore the neurovascular unit more effectively is a better approach for the treatment of ischemic stroke."

Two weeks after stroke, rats that had undergone cotransplantation showed less brain damage and improved behavioral performance on motor tasks compared with rats that had been treated with neural progenitor cells alone. "Our findings suggest that cotransplantation of neural and vascular cells is much more effective than transplantation of one cell type alone because these two cell types mutually support each other to promote recovery after stroke," Gao says.

###

Go here to see the original:
Stem cell-based transplantation approach improves recovery from stroke

Posted in Cell Medicine | Comments Off on Stem cell-based transplantation approach improves recovery from stroke

Stem Cell Doctor at Beverly Hills Orthopedic Institute Now Offering Regenerative Procedures for Achilles Tendonitis …

Posted: June 18, 2014 at 9:45 am

Beverly Hills, CA (PRWEB) June 16, 2014

The top stem cell doctors at Beverly Hills Orthopedic Institute are now offering regenerative medicine procedures for Achilles tendonitis and tears. The procedures include options for several types of stem cell procedures that can provide pain relief and help patients avoid surgery. Call (310) 438-5343 for more information and scheduling.

Achilles tendonitis or tears may bother patients for many months and not respond well to traditional treatments. This may include NSAIDS, bracing and steroid injections. While surgery for these conditions may be extremely successful, there is often a considerable rehabilitation and potential surgery complications.

Stem cell injections for Achilles tears or tendonitis have been a revolutionary treatment. This may include bone marrow derived injections, or amniotic derived stem cell procedures. Both offer exceptional concentrations of stem cells, growth factors and additional reparative materials.

The procedures are performed as an outpatient, with the amniotic derived material coming from consenting donors after scheduled c-sections. There is no fetal material used, negating any ethical concerns.

Dr. Raj at Beverly Hills Orthopedic Institute is a Double Board Certified orthopedic doctor. He treats patients from weekend warriors to amateur and professional athletes, along with celebrities, executives, manual laborers and grandparents.

For more information and scheduling, call (310) 438-5343.

Read the original post:
Stem Cell Doctor at Beverly Hills Orthopedic Institute Now Offering Regenerative Procedures for Achilles Tendonitis ...

Posted in Cell Medicine | Comments Off on Stem Cell Doctor at Beverly Hills Orthopedic Institute Now Offering Regenerative Procedures for Achilles Tendonitis …

Page 105«..1020..104105106107..110120..»